Tocqueville Asset Management’s TG Therapeutics TGTX Stock Holding History

Tocqueville Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-13,900	Closed	-$463K	–	768
2021 Q3	$463K	Sell	13,900 -2,000	-13%	-$61.9K	0.01%	557
2021 Q2	$617K	Buy	15,900 +2,150	+16%	+$84.4K	0.01%	515
2021 Q1	$663K	Buy	13,750 +400	+3%	+$19.2K	0.01%	511
2020 Q4	$694K	Sell	13,350 -1,150	-8%	-$38.9K	0.01%	492
2020 Q3	$388K	Buy	14,500 +2,500	+21%	+$57.5K	0.01%	538
2020 Q2	$234K	Buy	+12,000	New	+$193K	﹤0.01%	605

Other funds holding TGTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Tocqueville Asset Management's TGTX Position: Q4 2021 in Review

Tocqueville Asset Management sold out of TG Therapeutics (TGTX) in Q4 2021, closing a stake of 13,900 shares — an estimated $463K sold.

Tocqueville Asset Management first reported a position in TGTX in Q2 2020 and held it in 6 quarters. The position peaked at $694K in Q4 2020. 194 funds tracked by Wall St. Rank hold TGTX as of Q4 2021.

Tocqueville Asset Management reported no remaining TG Therapeutics position as of Q4 2021 after selling out during the quarter.
Tocqueville Asset Management sold 13,900 TG Therapeutics shares in Q4 2021, an estimated $463K.
Tocqueville Asset Management first reported a position in TG Therapeutics in Q2 2020 and held it in 6 quarters.
Tocqueville Asset Management's TG Therapeutics position peaked at $694K in Q4 2020.
194 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2021.

Based on Tocqueville Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.